Mobile website
Archive > Volume 24 Issue 2 > 2017,24(2):103-111. DOI:10.3872/j.issn.1007-385X.2017.02.001 Prev Next
Expert Forum
Cancer evolution-development: novel theory based on studies of inflammation-cancer transformation
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Malignant transformation induced by chronic inflammation represents a common process of carcinogenesis for the majority of cancers. Authors presented a novel theory framework of cancer evolution-development (Cancer Evo-Dev) based on the evidence chains from genome researches, somatic mutations/epigenetic alterations-related signaling-pathway studies, and epidemiological investigations. The central contents of this theory include the following aspects: the interactions of genetic predispositions of key immune/inflammatory molecules and environmental exposures induce and maintain the chronic non-resolving inflammation. Under the microenvironment of non-resolving inflammation, cytidine deaminases are persistently trans-activated by proinflammatory factors and bridge chronic inflammation and cancers by promoting the generation of vast somatic mutations. Most mutant cells are eliminated in the hostile inflammatory microenvironments, only a small percentage of the mutant cells undergo de-differentiation to acquire the characteristics of “stem-ness” via altering signaling-pathways by somatic mutations and inflammation-related epigenetic modifications, and develop into cancer initiating cells. This carcinogenic process follows the evolution regulation of “mutation-selection-adaptation”. Cancer Evo-Dev not only facilitates understanding the basic mechanism of inflammation-cancer transformation, but also contributes to the development of specific prophylaxis, prediction, and targeted therapy of cancers.
Keywords:
Project Supported:
Project supported by the National Key Basic Research Program of China（No. 2015CB554000）, and the Major Research Plan of National Natural Scientific Foundation of China（No. 91529305）
Clc Number:
